Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

The research provides new insights into how headaches develop in raised intracranial pressure (ICP)-related conditions and suggest new treatments for patients.

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

According to Kiran Jones, a clinical pharmacist at Oxford Online Pharmacy, some of the most concerning side effects of GLP-1 ...

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

While GLP-1 receptor agonists are widely used to treat ... There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists ...